Rapid risk/outbreaks assessment aim at supporting the countries and the European Commission in their preparedness and response to a public health threat. They provide a timely summary and risk assessment of a public health threat for EU/EEA countries related to a specific event. They also include potential options for response. As outbreaks or public health events develop, ECDC may issue updated risk assessments.
This rapid risk assessment update appraises the risk for spread of C. auris in hospitals in the European Union and European Economic Area (EU/EEA) countries
The rise in Europe of Candida auris infections, a difficult-to-control fungus, is of concern. The fungus spreads easily in healthcare settings, can cause invasive infections, and is also associated with resistance to multiple classes of anti-fungal medication.
To support the annual World Health Organization (WHO) “SAVE LIVES: Clean your Hands” campaign, ECDC is launching two new pages of its directory of online resources on infection prevention and control.
The goal of this systematic review is to update the 2011 ECDC risk assessment. Evidence from this review will be used to develop guidance on this topic.
This systematic review seeks to identify evidence for the effectiveness of targeted infection control measures to control the spread and transmission of ESBL-E when transferring patients between healthcare settings, especially when the transfer is cross-border.
From 21 to 28 November 2014, nearly 700 organisations across Europe will host activities to increase awareness of the personal and public health benefits of HIV testing. As HIV infection can remain asymptomatic for a long time and a substantial number of infected persons across Europe are unaware of their infection, ECDC supports the aims of this second European HIV testing week.
ECDC gathered guidance documents on prevention and control of infection with carbapenem-resistant Enterobacteriaceae (CRE) available online, published by EU/EEA Member States, ECDC, other agencies and scientific societies.
Monitoring and responding to HIV and hepatitis C among people who inject drugs is the focus of two new reports from the EU drugs agencies EMCDDA and ECDC.